BioCentury | Jul 8, 2019
Clinical News

July 8 Clinical Quick Takes: Hemophilia data from Sangamo-Pfizer, Novo; plus GamaMabs, Xarelto and more

...Xetra:BAYN) for Xarelto, presented full trial data at ISTH. GamaMabs combo leads to 40% PFS GamaMabs Pharma S.A....
...Tissue factor pathway inhibitor Sandi Wong, Staff Writer GM102, 3c23k Lonsurf, trifluridine/tipiracil (TAS-102) PF-07055480, SB-525 Xarelto, rivaroxaban (BAY 59-7939) Bayer AG GamaMabs Pharma S.A. Janssen Johnson...
BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

...being tested in solid tumors, including an expansion cohort of patients with MSS-CRC. Researchers from GamaMabs Pharma S.A....
...5 biliary tract cancer patients and 2 of 6 CRC patients 2519 LFB S.A. / GamaMabs Pharma S.A....
...CytomX Therapeutics Inc. (NASDAQ:CTMX), South San Francisco, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. GamaMabs Pharma S.A....
BioCentury | Jun 1, 2018
Clinical News

GamaMabs reports Phase I data for GM102 in gynecological cancers

...from expansion cohorts in epithelial ovarian and granulosa ovarian cancers are expected early next year. GamaMabs Pharma S.A....
...rights to the product from LFB S.A. (Les Ulis, France). Claire Quang GM102, 3c23k American Society of Clinical Oncology ASCO GamaMabs Pharma S.A. LFB...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

...inhibitor of glioblastoma stem cell marker oligodendrocyte transcription factor 2 (OLIG2) Active Preclinical testing ongoing GamaMabs Pharma S.A....
BioCentury | Nov 5, 2016
Finance

Vive la biotech

...potential future bellwethers named by VCs included antiviral play Enyo Pharma S.A.S. and immuno-oncology company GamaMabs Pharma S.A....
...Eligo Bioscience S.A.S., Paris, France Enterome Bioscience S.A., Paris, France Enyo Pharma S.A.S., Lyon, France GamaMabs Pharma S.A....
...its CAR T.” BioCentury (2014) Stephen Hansen, Associate Editor Cellectis S.A. DBV Technologies S.A. Eligo Bioscience S.A.S. Enterome Bioscience S.A. Enyo Pharma GamaMabs Pharma S.A. Genfit...
BioCentury | Aug 8, 2016
Clinical News

GM102: Phase Ia/Ib started

...Ib expansion in 30 patients. GamaMabs has exclusive, worldwide rights to the product from LFB. GamaMabs Pharma S.A....
BioCentury | Dec 21, 2015
Financial News

GamaMabs Pharma completes venture financing

GamaMabs Pharma S.A. , Toulouse, France Business: Cancer, Antibodies Date completed: 2015-12-15 Type: Venture financing Raised: EUR15 million ($16.4 million) Investors: BioDiscovery 4; InnoBio Fund; IRDINov; Alto Invest; iXO Private Equity WIR Staff cancer...
BioCentury | Dec 15, 2015
Financial News

GamaMabs raises EUR 15M in series B

GamaMabs Pharma S.A. (Tolouse, France) raised EUR 15 million ($16.4 million) in a series B round led by new investor Edmond de Rothschild Investment Partners (EdRIP) via its BioDiscovery 4 fund. Existing investors InnoBio, Irdinov,...
BioCentury | Jun 22, 2015
Emerging Company Profile

Singling out ovarian cancer

...undisclosed targets. Companies and Institutions Mentioned GamaMabs Pharma S.A., Toulouse, France LFB S.A., Les Ulis, France Sidebars GamaMabs Pharma S.A....
BioCentury | Oct 14, 2013
Finance

First mover money

...throwing their hat in the cancer stem cell ring, providing €3.1 million ($4.2 million) to GamaMabs Pharma S.A....
Items per page:
1 - 10 of 13
BioCentury | Jul 8, 2019
Clinical News

July 8 Clinical Quick Takes: Hemophilia data from Sangamo-Pfizer, Novo; plus GamaMabs, Xarelto and more

...Xetra:BAYN) for Xarelto, presented full trial data at ISTH. GamaMabs combo leads to 40% PFS GamaMabs Pharma S.A....
...Tissue factor pathway inhibitor Sandi Wong, Staff Writer GM102, 3c23k Lonsurf, trifluridine/tipiracil (TAS-102) PF-07055480, SB-525 Xarelto, rivaroxaban (BAY 59-7939) Bayer AG GamaMabs Pharma S.A. Janssen Johnson...
BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

...being tested in solid tumors, including an expansion cohort of patients with MSS-CRC. Researchers from GamaMabs Pharma S.A....
...5 biliary tract cancer patients and 2 of 6 CRC patients 2519 LFB S.A. / GamaMabs Pharma S.A....
...CytomX Therapeutics Inc. (NASDAQ:CTMX), South San Francisco, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. GamaMabs Pharma S.A....
BioCentury | Jun 1, 2018
Clinical News

GamaMabs reports Phase I data for GM102 in gynecological cancers

...from expansion cohorts in epithelial ovarian and granulosa ovarian cancers are expected early next year. GamaMabs Pharma S.A....
...rights to the product from LFB S.A. (Les Ulis, France). Claire Quang GM102, 3c23k American Society of Clinical Oncology ASCO GamaMabs Pharma S.A. LFB...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

...inhibitor of glioblastoma stem cell marker oligodendrocyte transcription factor 2 (OLIG2) Active Preclinical testing ongoing GamaMabs Pharma S.A....
BioCentury | Nov 5, 2016
Finance

Vive la biotech

...potential future bellwethers named by VCs included antiviral play Enyo Pharma S.A.S. and immuno-oncology company GamaMabs Pharma S.A....
...Eligo Bioscience S.A.S., Paris, France Enterome Bioscience S.A., Paris, France Enyo Pharma S.A.S., Lyon, France GamaMabs Pharma S.A....
...its CAR T.” BioCentury (2014) Stephen Hansen, Associate Editor Cellectis S.A. DBV Technologies S.A. Eligo Bioscience S.A.S. Enterome Bioscience S.A. Enyo Pharma GamaMabs Pharma S.A. Genfit...
BioCentury | Aug 8, 2016
Clinical News

GM102: Phase Ia/Ib started

...Ib expansion in 30 patients. GamaMabs has exclusive, worldwide rights to the product from LFB. GamaMabs Pharma S.A....
BioCentury | Dec 21, 2015
Financial News

GamaMabs Pharma completes venture financing

GamaMabs Pharma S.A. , Toulouse, France Business: Cancer, Antibodies Date completed: 2015-12-15 Type: Venture financing Raised: EUR15 million ($16.4 million) Investors: BioDiscovery 4; InnoBio Fund; IRDINov; Alto Invest; iXO Private Equity WIR Staff cancer...
BioCentury | Dec 15, 2015
Financial News

GamaMabs raises EUR 15M in series B

GamaMabs Pharma S.A. (Tolouse, France) raised EUR 15 million ($16.4 million) in a series B round led by new investor Edmond de Rothschild Investment Partners (EdRIP) via its BioDiscovery 4 fund. Existing investors InnoBio, Irdinov,...
BioCentury | Jun 22, 2015
Emerging Company Profile

Singling out ovarian cancer

...undisclosed targets. Companies and Institutions Mentioned GamaMabs Pharma S.A., Toulouse, France LFB S.A., Les Ulis, France Sidebars GamaMabs Pharma S.A....
BioCentury | Oct 14, 2013
Finance

First mover money

...throwing their hat in the cancer stem cell ring, providing €3.1 million ($4.2 million) to GamaMabs Pharma S.A....
Items per page:
1 - 10 of 13